MF

Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Monday, December 11, 2023

“Additionally, we are encouraged by the preliminary data from the lowest three dose cohorts from our ongoing Phase 2 clinical trial in MF.

Key Points: 
  • “Additionally, we are encouraged by the preliminary data from the lowest three dose cohorts from our ongoing Phase 2 clinical trial in MF.
  • Data for hematological response and markers of hematopoiesis were presented from exploratory analyses of these mITT24 patients.
  • All data presented from this trial is as of the data cut-off date.
  • 13 of those 18 patients (72.2%) achieved TI for at least 24 weeks over the first 48 weeks of treatment.

Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Monday, December 11, 2023

“We are thrilled to see this level of hematologic activity so early during dose escalation and in a range of patient types.

Key Points: 
  • “We are thrilled to see this level of hematologic activity so early during dose escalation and in a range of patient types.
  • The trial also includes patients who may or may not be receiving concomitant janus kinase (JAK) inhibitor therapy.
  • In the phase 1b dose-escalation phase, DISC-0974 is administered subcutaneously every 4 weeks for up to 6 treatments.
  • These data were presented at the 65th American Society of Hematology (ASH) Annual Meeting in San Diego, California and the poster is available on the ASH platform.

CURE Media Group announces winners of the 2023 MPN Heroes® Recognition Program

Retrieved on: 
Saturday, December 9, 2023

CRANBURY, N.J., Dec. 08, 2023 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to more than 1 million patients, survivors and caregivers, today announced the recipients of the 2023 MPN Heroes® Recognition Program.

Key Points: 
  • CRANBURY, N.J., Dec. 08, 2023 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to more than 1 million patients, survivors and caregivers, today announced the recipients of the 2023 MPN Heroes® Recognition Program.
  • Marilyn Kay Edwards is an MPN Hero for her outreach as an MPN peer with CHAMPN, the Community Voice Champion Program.
  • Marina Kremyanskaya, M.D., Ph.D., is an MPN Hero because of her extraordinary impact as an educator, physician and leader in MPN research.
  • Incyte partners with CURE Media Group to support the program, with CURE hosting the annual MPN Heroes recognition ceremony.

Gong cha Signs Two New Master Franchisees Across the Americas

Retrieved on: 
Monday, December 11, 2023

The two deals are projected to grow Gong cha’s presence in the Americas by more than 100 stores.

Key Points: 
  • The two deals are projected to grow Gong cha’s presence in the Americas by more than 100 stores.
  • Since 2014, Gong cha Americas has grown at a rapid pace, opening more than 400 locations throughout the U.S., Canada, and Mexico.
  • The master franchise rights for the Great Pacific Northwest have been awarded to Master Franchisee Ajay Keshap.
  • “We’re proud to be partnering with Ajay, Justin and Monica to bring Gong cha to new markets across the Pacific Northwest and Central America,” says Geoff Henry, Gong cha’s President of the Americas.

Geron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis

Retrieved on: 
Wednesday, December 6, 2023

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the Phase 3 IMpactMF clinical trial investigating the Company’s first-in-class telomerase inhibitor, imetelstat, versus best available therapy (BAT) in patients with relapsed/refractory myelofibrosis (MF).

Key Points: 
  • Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the Phase 3 IMpactMF clinical trial investigating the Company’s first-in-class telomerase inhibitor, imetelstat, versus best available therapy (BAT) in patients with relapsed/refractory myelofibrosis (MF).
  • “This is the first Phase 3 trial to evaluate overall survival as a primary endpoint in relapsed/refractory MF and is also the first Phase 3 trial investigating a telomerase inhibitor in this patient population.
  • “There is therefore a very pressing need for treatments that can improve survival in relapsed/refractory MF.
  • A median OS of 29.9 months in imetelstat 9.4 mg/kg arm was observed in IMbark Phase 2, compared to 14-16 months median OS for historical controls for these JAKi relapsed/refractory MF patients.

AGCO Brands Win Six 2024 AE50 Awards

Retrieved on: 
Wednesday, December 6, 2023

AGCO Corporation (NYSE: AGCO), a global leader in the design, manufacture, and distribution of agricultural machinery and precision ag technology, announced today that six of its products and solutions have been recognized with prestigious 2024 AE50 awards from the American Society of Agricultural and Biological Engineers (ASABE) .

Key Points: 
  • AGCO Corporation (NYSE: AGCO), a global leader in the design, manufacture, and distribution of agricultural machinery and precision ag technology, announced today that six of its products and solutions have been recognized with prestigious 2024 AE50 awards from the American Society of Agricultural and Biological Engineers (ASABE) .
  • AGCO’s 2024 awards span its Fendt®, Massey Ferguson® and Precision Planting® brands, confirming consistent excellence across its product lines and cementing the company as agriculture’s leading innovator of farmer-focused solutions.
  • View the full release here: https://www.businesswire.com/news/home/20231206827750/en/
    AGCO announced that six of its products and solutions won the prestigious 2024 AE50 Award for innovation and engineering excellence.
  • (Photo: Business Wire)
    “AGCO is greatly honored by ASABE’s recognition again this year,” said Eric Hansotia, AGCO President, Chairman, and Chief Executive Officer.

GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative

Retrieved on: 
Monday, November 13, 2023

GSK plc (LSE/NYSE: GSK) has partnered with former Queer Eye star and interior designer Thom Filicia to launch Mapping Myelofibrosis, a new health education initiative aiming to help those impacted by myelofibrosis (MF) better navigate the disease.

Key Points: 
  • GSK plc (LSE/NYSE: GSK) has partnered with former Queer Eye star and interior designer Thom Filicia to launch Mapping Myelofibrosis, a new health education initiative aiming to help those impacted by myelofibrosis (MF) better navigate the disease.
  • This year marks the 10-year anniversary of Filicia donating bone marrow to his brother, who was diagnosed with MF a few months prior to the transplant.
  • This experience led me to team up with GSK on Mapping Myelofibrosis to continue raising awareness of this complex blood cancer.”
    Mapping Myelofibrosis includes the launch of a website featuring educational resources about MF, community stories, and messages from Filicia.
  • In developing the initiative, GSK sought input from the MF community through collaborations with organizations including the MPN Research Foundation (MPNRF) and MPN Advocacy & Education International (MPN A&E).

Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023

Third Quarter 2023 Financial Results:

Key Points: 
  • Third Quarter 2023 Financial Results:
    Cash Position: Cash and cash equivalents were $370.5 million as of September 30, 2023, which are expected to fund our operational plans well into 2026.
  • Research and Development Expenses: R&D expenses were $14.4 million for the quarter ended September 30, 2023, as compared to $7.9 million for the quarter ended September 30, 2022.
  • General and Administrative Expenses: G&A expenses were $4.5 million for the quarter ended September 30, 2023, as compared to $2.6 million for the same period in 2022.
  • Net Loss: Net loss was $14.1 million for the quarter ended September 30, 2023, as compared to $16.2 million for the third quarter of 2022.

AGCO to Showcase Technology Stack and Sustainable Solutions at Agritechnica 2023

Retrieved on: 
Thursday, November 9, 2023

AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology, will once again host thousands of farmers at the world's largest ag fair, Agritechnica.

Key Points: 
  • AGCO (NYSE: AGCO), a global leader in the design, manufacture and distribution of agricultural machinery and precision ag technology, will once again host thousands of farmers at the world's largest ag fair, Agritechnica.
  • “It's great to be back at Agritechnica and meeting with our farmers and dealers,” said Eric Hansotia, Chairman, President and Chief Executive Officer of AGCO.
  • “AGCO has an unbelievable lineup – from clean energy options to automation, autonomy and AI solutions.
  • Valtra S series launch with SmartTurn technology that allows farmers autonomous field driving features for higher precision and less fatigue.

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023

WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today reported its financial results for the third quarter ended September 30, 2023 and provided a corporate update.  

Key Points: 
  • The Company plans to submit results of the BEACON study for presentation at an upcoming medical meeting.
  • In August 2023, Lyra announced completion of enrollment in the pivotal Phase 3 ENLIGHTEN I clinical trial.
  • Cash, cash equivalents and short-term investments as of September 30, 2023 were $102.6 million, compared with $116.2 million at June 30, 2023.
  • Net loss for the quarter ended September 30, 2023 was $15.7 million compared to $14.8 million for the same period in 2022.